Table 7 Types of Nonimmediate Reactions Commonly Tested Using Patch Tests
| Â | Europe, n (%) | Asia Pacific, n (%) | North America, n (%) | Latin America, n (%) | Africa Middle East, n (%) | Region Not Specified, n (%) | Total (n = 47), n (%) |
|---|---|---|---|---|---|---|---|
Maculopapular exanthema | 18 (38.3) | 2 (4.3) | 4 (8.5) | 5 (10.6) | 1 (2.1) | 1 (2.1) | 31 (66.0) |
Drug induced hypersensitivity syndrome (DIHS) | 14 (29.8) | 6 (12.8) | 3 (6.4) | 4 (8.5) | 2 (4.3) | 1 (2.1) | 30 (63.8) |
Fixed drug eruption | 14 (29.8) | 3 (6.4) | 2 (4.3) | 4 (8.5) | 4 (8.5) | 2 (4.3) | 29 (61.7) |
AGEP | 15 (31.9) | 3 (6.4) | 4 (8.5) | 3 (6.4) | 0 (0.0) | 1 (2.1) | 26 (55.3) |
Stevens-Johnson syndrome | 13 (27.7) | 2 (4.3) | 0 (0.0) | 4 (8.5) | 2 (4.3) | 1 (2.1) | 22 (46.8) |
TEN | 8 (17.0) | 1 (2.1) | 0 (0.0) | 3 (6.4) | 1 (2.1) | 1 (2.1) | 14 (29.8) |
Immunobullous eruptions | 8 (17.0) | 1 (2.1) | 0 (0.0) | 2 (4.3) | 0 (0.0) | 1 (2.1) | 12 (25.5) |
Vasculitis | 7 (14.9) | 1 (2.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 8 (17.0) |
Blood dyscracias | 1 (2.1) | 1 (2.1) | 0 (0.0) | 1 (2.1) | 0 (0.0) | 0 (0.0) | 3 (6.4) |